retatrutide clinical trials safety efficacy and of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled Clinical trial for chronic obesity

Medicare cannot cover Ozempic when prescribed for weight loss

The STEP trial extension data showed that participants regained approximately 40 percent of lost weight within 28 weeks of stopping semaglutide

GLP-1 drugs also lower blood sugar levels and slow gastric emptying which reduces hunger to levels that cause natural caloric restriction and thus, weight loss

This combination approach addresses cardiovascular risk through multiple mechanisms, providing redundancy and greater protection than either drug alone

Focus on protein first at each meal, then add vegetables and carbs as tolerated

First, let me caution that this is just a mouse study, so it may not hold true in humans